Occam Places Chief Legal Officer at Public Oncology Biotech
.jpg)
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company focused on the development and commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. In August 2023, Occam placed Scott Samuels as SVP, Chief Legal Officer, and Corporate Secretary.
Prior to Geron, Scott served as Chief Legal and Compliance Officer of clinical-stage biotech, Prilenia Therapeutics. He was formerly the founding General Counsel of BeiGene, where he strategically built the company’s legal and compliance functions. Scott began his operating career at ARIAD after 17 years spent in the corporate and life sciences practices of Mintz Levin. Scott holds a J.D. from George Mason University and a B.A. in philosophy from Cornell University.
Geron is a longstanding client for whom Occam has previously placed three independent Board members, John, McDonald, Dawn Bir, and Liz O'Farrell, and more recently, Chief Business Officer Edward Koval and VP Investor Relations & Corporate Communications Aron Feingold.
Occam Global is an executive recruiting and leadership advisory firm with specialties across technological fields including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.